These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 19259064)

  • 41. Characteristics of Minimally Oversized Adeno-Associated Virus Vectors Encoding Human Factor VIII Generated Using Producer Cell Lines and Triple Transfection.
    Nambiar B; Cornell Sookdeo C; Berthelette P; Jackson R; Piraino S; Burnham B; Nass S; Souza D; O'Riordan CR; Vincent KA; Cheng SH; Armentano D; Kyostio-Moore S
    Hum Gene Ther Methods; 2017 Feb; 28(1):23-38. PubMed ID: 28166648
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
    Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
    Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
    [TBL] [Abstract][Full Text] [Related]  

  • 43. What´s new in Gene Therapy of Hemophilia.
    Rodriguez-Merchan EC
    Curr Gene Ther; 2018; 18(2):107-114. PubMed ID: 29446741
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Generation and characterization of human hematopoietic cell lines expressing factor VIII.
    Tonn T; Herder C; Becker S; Seifried E; Grez M
    J Hematother Stem Cell Res; 2002 Aug; 11(4):695-704. PubMed ID: 12201958
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity.
    Shi Q; Fahs SA; Wilcox DA; Kuether EL; Morateck PA; Mareno N; Weiler H; Montgomery RR
    Blood; 2008 Oct; 112(7):2713-21. PubMed ID: 18495954
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An induced pluripotent stem cell-mediated and integration-free factor VIII expression system.
    Yakura Y; Ishihara C; Kurosaki H; Kazuki Y; Komatsu N; Okada Y; Doi T; Takeya H; Oshimura M
    Biochem Biophys Res Commun; 2013 Feb; 431(2):336-41. PubMed ID: 23291180
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice.
    Gallo-Penn AM; Shirley PS; Andrews JL; Kayda DB; Pinkstaff AM; Kaloss M; Tinlin S; Cameron C; Notley C; Hough C; Lillicrap D; Kaleko M; Connelly S
    Hum Gene Ther; 1999 Jul; 10(11):1791-802. PubMed ID: 10446919
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A mice.
    Brown BD; Shi CX; Rawle FE; Tinlin S; McKinven A; Hough C; Graham FL; Lillicrap D
    J Thromb Haemost; 2004 Jan; 2(1):111-8. PubMed ID: 14717974
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correction of murine hemophilia A following nonmyeloablative transplantation of hematopoietic stem cells engineered to encode an enhanced human factor VIII variant using a safety-augmented retroviral vector.
    Ramezani A; Hawley RG
    Blood; 2009 Jul; 114(3):526-34. PubMed ID: 19470695
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene.
    Staber JM; Pollpeter MJ; Anderson CG; Burrascano M; Cooney AL; Sinn PL; Rutkowski DT; Raschke WC; McCray PB
    Gene Ther; 2017 Nov; 24(11):742-748. PubMed ID: 28905885
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy.
    Connelly S; Andrews JL; Gallo AM; Kayda DB; Qian J; Hoyer L; Kadan MJ; Gorziglia MI; Trapnell BC; McClelland A; Kaleko M
    Blood; 1998 May; 91(9):3273-81. PubMed ID: 9558383
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette.
    Lu H; Chen L; Wang J; Huack B; Sarkar R; Zhou S; Xu R; Ding Q; Wang X; Wang H; Xiao W
    Hum Gene Ther; 2008 Jun; 19(6):648-54. PubMed ID: 18500941
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice.
    Bunting S; Zhang L; Xie L; Bullens S; Mahimkar R; Fong S; Sandza K; Harmon D; Yates B; Handyside B; Sihn CR; Galicia N; Tsuruda L; O'Neill CA; Bagri A; Colosi P; Long S; Vehar G; Carter B
    Mol Ther; 2018 Feb; 26(2):496-509. PubMed ID: 29292164
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A.
    Brown BD; Shi CX; Powell S; Hurlbut D; Graham FL; Lillicrap D
    Blood; 2004 Feb; 103(3):804-10. PubMed ID: 14512318
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A.
    Shi Q; Wilcox DA; Fahs SA; Fang J; Johnson BD; DU LM; Desai D; Montgomery RR
    J Thromb Haemost; 2007 Feb; 5(2):352-61. PubMed ID: 17269937
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficient adenoviral vector transduction and expression of functional human factor VIII in cultured primary human hepatocytes.
    Andrews JL; Weaver L; Kaleko M; Connelly S
    Haemophilia; 1999 May; 5(3):160-8. PubMed ID: 10444282
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sustained phenotypic correction of hemophilia a mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells.
    Moayeri M; Ramezani A; Morgan RA; Hawley TS; Hawley RG
    Mol Ther; 2004 Nov; 10(5):892-902. PubMed ID: 15509507
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Onco-retroviral and lentiviral vector-based gene therapy for hemophilia: preclinical studies.
    Van Damme A; Chuah MK; Collen D; VandenDriessche T
    Semin Thromb Hemost; 2004 Apr; 30(2):185-95. PubMed ID: 15118930
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.
    Lei TC; Scott DW
    Blood; 2005 Jun; 105(12):4865-70. PubMed ID: 15769892
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In Vitro FVIII-Encoding Transgenic Mesenchymal Stem Cells Maintain Successful Coagulation in FVIII-Deficient Plasma Mimicking Hemophilia A.
    Hemşinlioğlu C; Aslan ES; Taştan C; Çakırsoy D; Turan RD; Seyis U; Elek M; Sır Karakuş G; Günaydın ÖS; Abanuz S; Kançağı DD; Yurtsever B; Yalçın K; Kasap M; Ovalı E
    Turk J Haematol; 2023 May; 40(2):118-124. PubMed ID: 37022209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.